This blog by Healthgevity explores a multi-pathway approach to women’s hormonal health, from PMS and PCOS through perimenopause and menopause, covering endocrine, gut, mood, sleep and metabolic pathways. Discover how HERgevity™ Balance supports these interconnected pathways with a non-hormonal, evidence-informed formula.
Why supporting multiple interconnected pathways may offer a more complete approach from PMS through menopause
Women’s hormonal health is rarely a single-hormone problem. So why are so many non-hormonal formulas built around a single pathway?
Across the reproductive years, perimenopause, and menopause, endocrine signaling, the gut environment, mood, sleep, and metabolic health continually interact. A patient experiencing changes in cycle regularity, vasomotor symptoms, mood, or overall well-being may therefore benefit from a broader strategy than focusing exclusively on estrogen.
This systems-based perspective is the foundation of HERgevity™ Balance by Healthgevity®, a non-hormonal, multi-pathway formula designed to support complementary pathways involved in women’s hormonal health.
Targeted Support During the Menopausal Transition
MENOFELIS®, a standardized Rheum rhaponticum root extract (ERr 731), provides one of the most clinically established components of the formula.
MENOFELIS® has been evaluated across multiple clinical studies in perimenopausal and menopausal women, with research reporting improvements in menopausal symptoms, anxiety, general well-being, and quality-of-life measures.¹⁻³ A 2024 systematic review and meta-analysis further evaluated its efficacy for menopausal symptoms.⁴
Importantly, safety has also been evaluated. A 2025 study examining MENOFELIS® prescriptions and subsequent breast cancer found no association between MENOFELIS® use and an increased risk of breast cancer.⁵ For practitioners evaluating non-hormonal approaches to menopausal support, this adds an important dimension to the ingredient’s growing body of clinical evidence.
Rather than approaching menopause solely by supplying exogenous hormones, MENOFELIS® provides practitioners with a well-studied botanical option for non-hormonal menopausal support.
Endocrine Support Across Different Life Stages
Women’s hormonal needs can look dramatically different during the reproductive years, PCOS/PMOS, perimenopause, and menopause.
Xeya™ Modern Shatavari, a standardized Asparagus racemosus root extract, brings a broader endocrine dimension to the formula.
In a 2025 randomized, double-blind, placebo-controlled study, standardized Shatavari supplementation was associated with improvements in hormonal balance, menstrual health, and vasomotor symptoms in perimenopausal women.⁶
A separate randomized controlled trial in women with PCOS reported improvements in ovarian morphology, menstrual regularity, and metabolic parameters.⁷
Together, these findings make Shatavari particularly interesting for a formula designed to support women across multiple stages of hormonal transition.
The Gut–Hormone Connection
The gut is increasingly recognized as an important component of systemic and hormonal health.
PoZibio®, a heat-treated Lacticaseibacillus paracasei D3.5 postbiotic, introduces a gut-barrier component rarely addressed in conventional women’s hormone formulas.
Preclinical research on heat-killed L. paracasei D3.5 demonstrated improvements in age-related intestinal barrier dysfunction and inflammatory signaling.⁸ Broader postbiotic research also highlights potential roles for microbial-derived compounds in supporting intestinal barrier integrity and host physiology.⁹
For practitioners, this creates an opportunity to think beyond the ovaries and consider the intestinal environment as part of a more comprehensive approach to women’s health.
Mood and Neuroendocrine Health
Hormonal transitions frequently extend beyond physical symptoms to changes in mood, stress resilience, and sleep.
Affron®, a standardized saffron extract, has been investigated specifically in perimenopausal women. In a randomized, double-blind, placebo-controlled trial, affron® supplementation was associated with improvements in psychological symptoms related to menopause.¹⁰ Additional randomized research has demonstrated benefits for mood and emotional well-being in adults.¹¹
This provides an important neuroendocrine dimension to a formula designed for the whole patient—not simply her hormone levels.
Completing the Multi-Pathway Strategy
AstraGin® and Ioniplex® provide additional nutrient-utilization and mineral support, complementing the primary bioactive ingredients.
The result is a broader clinical framework:
Endocrine signaling → Menopausal support → Gut-barrier health → Mood & neuroendocrine health → Nutrient utilization
HERgevity™ Balance is not intended to replace hormone replacement therapy when HRT is clinically indicated. Instead, it provides practitioners with a non-hormonal, multi-pathway option for women whose needs extend beyond a single hormone or symptom.
Because women’s hormonal health is interconnected—and the nutritional strategy supporting it should be as well.
About the Author
Samantha Antonelli, INHC is a board-certified health coach and 2016 graduate of the Institute for Integrative Nutrition (IIN). For over a decade, Samantha has specialised in supporting functional and integrative medicine physicians, helping translate advanced diagnostic testing into actionable, personalised care. She currently brings this expertise to Healthgevity, where she works with practitioners to help bridge clinical science and patient-level implementation.
Working alongside practitioners who combine specialised lab testing with targeted supplementation, Samantha bridges the gap between complex biomarker data and day-to-day patient implementation — helping patients understand their results, adhere to individualised supplement protocols, and sustain the lifestyle changes that make root-cause care effective. This experience has given Samantha a strong working familiarity with functional lab panels and how they inform nutrition, lifestyle, and supplement strategy alongside a physician's clinical plan.
References
- Kaszkin-Bettag M, et al. Altern Ther Health Med. 2008;14(6):32-38.
- Kaszkin-Bettag M, et al. Altern Ther Health Med. 2009;15(1):24-34.
- Kaszkin-Bettag M, et al. Menopause. 2007;14(2):270-283.
- Dubey VP, et al. J Biomed Res. 2024;38(3):278-286. doi:10.7555/JBR.37.20230219.
- Heger PW, et al. Breast Cancer Res Treat. 2025;212(1):139-148. doi:10.1007/s10549-025-07711-9.
- Yadav P, et al. J Am Nutr Assoc. 2025;44(8):754-764.
- Kondamudi S, et al. Food Nutr Res. 2025;69. doi:10.29219/fnr.v69.13244.
- Wang S, et al. GeroScience. 2020;42(1):333-352. doi:10.1007/s11357-019-00137-4.
- Żółkiewicz J, et al. Nutrients. 2020;12(8):2189. doi:10.3390/nu12082189.
- Lopresti AL, Smith SJ. J Menopausal Med. 2021;27(2):66-78. doi:10.6118/jmm.21002.
- Kell G, et al. Complement Ther Med. 2017;33:58-64. doi:10.1016/j.ctim.2017.06.001.